1. Shi, A., Tao, Z., Wei, P.&Zhao, J. Epidemiological aspects of heart diseases. Exp Ther Med. 12, 1645-1650 (2016).
2. Organization, W. H. Cardiovascular diseases (CVDs). WHO. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2017).
3. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 390, 1151-1210 (2017).
4. Mahmoud, I.&Sulaiman, N. Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study. BMJ Open. 9, e031969 (2019).
5. Sulaiman, N., et al. Prevalence of overweight and obesity in United Arab Emirates Expatriates: the UAE National Diabetes and Lifestyle Study. Diabetol Metab Syndr. 9, 88 (2017).
6. Stone, N. J., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63, 2889-934 (2014).
7. Wilson, P. W. F., et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 73, 3210-3227 (2019).
8. Grundy, S. M.&Stone, N. J. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. JAMA Cardiol. 4, 589-591 (2019).
9. Rosenson, R. S. Statin non-adherence: clinical consequences and proposed solutions. F1000Res. 5 (2016).
10. Nguyen, P. V.&Biron, P. Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. J Am Coll Cardiol. 65, 2768-9 (2015).
11. Tsuyuki, R. T., et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 162, 1149-55 (2002).
12. Yun, H., et al. Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction. J Am Heart Assoc. 4 (2015).
13. Santschi, V., Chiolero, A., Burnand, B., Colosimo, A. L.&Paradis, G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 171, 1441-53 (2011).
14. Machado, M., Nassor, N., Bajcar, J. M., Guzzo, G. C.&Einarson, T. R. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 42, 1195-207 (2008).
15. George, J., McNamara, K.&Stewart, K. The roles of community pharmacists in cardiovascular disease prevention and management. Australas Med J. 4, 266-72 (2011).
16. Dunn, S. P., et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 66, 2129-2139 (2015).
17. Bozovich, M., Rubino, C. M.&Edmunds, J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy. 20, 1375-83 (2000).
18. Tahaineh, L., Albsoul-Younes, A., Al-Ashqar, E.&Habeb, A. The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan. Int J Clin Pharm. 33, 229-36 (2011).
19. Tsuyuki, R. T., Rosenthal, M.&Pearson, G. J. A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott). 149, 283-292 (2016).
20. Doellner, J. F., Dettloff, R. W., DeVuyst-Miller, S.&Wenstrom, K. L. Prescriber acceptance rate of pharmacists' recommendations. J Am Pharm Assoc (2003). 57, S197-S202 (2017).
21. Meredith, A. H., Ramsey, D., Schmelz, A.&Berglund, R. Resident physicians' perceptions of ambulatory care pharmacy. Pharm Pract (Granada). 17, 1509 (2019).
22. Ganga, H. V., Slim, H. B.&Thompson, P. D. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 168, 6-15 (2014).
23. Cohen, J. D., Brinton, E. A., Ito, M. K.&Jacobson, T. A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 6, 208-15 (2012).
24. Sullivan, D., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Jama. 308, 2497-506 (2012).
25. Stroes, E., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 63, 2541-2548 (2014).
26. Moriarty, P. M., et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 9, 758-769 (2015).
27. Aburuz, S., et al. Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia. J Saudi Heart Assoc. 30, 349-355 (2018).
28. Cannon, C. P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 372, 2387-97 (2015).
29. Bedi, O., Dhawan, V., Sharma, P. L.&Kumar, P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 389, 695-712 (2016).
30. Yoshida, T.&Hayashi, M. Pleiotropic effects of statins on acute kidney injury: involvement of Kruppel-like factor 4. Clin Exp Nephrol. 21, 175-181 (2017).
31. Mohammad, S., et al. Pleiotropic Effects of Statins: Untapped Potential for Statin Pharmacotherapy. Curr Vasc Pharmacol. 17, 239-261 (2019).
32. Goff, D. C., Jr., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 129, S49-73 (2014).